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Background
Both inflammation and angiogenesis contribute to the
progression of abdominal aortic aneurysm (AAA) dis-
ease. RGD is a peptide binder of the avb3 integrin,
which is expressed highly on activated macrophages and
angiogenic endothelial cells. Human ferritin (HFn) is a
nanoscale protein cage with 12nm diameter and 8nm
interior cavity, which we have utilized as a platform for
molecular/cellular imaging. We can genetically intro-
duce RGD peptide to HFn. The purpose of this study is
to evaluate RGD-conjugated HFn iron oxide nanoparti-
cles for enhanced in vivo MRI of murine AAAs.
Methods
1) Mice - Murine AAAs were induced in Apo-E defi-
cient mice by angiotensin II infusion (1µg/kg/min), fol-
lowed by monitoring of aortic diameter by ultrasound.
Control mice were created by saline infusion.
2) RGD-conjugated HFn-iron oxide nanoparticles -
HFn was genetically engineered to display 24 copies of
an RGD peptide on the exterior surface of the protein
cage. Magnetite (Fe3O4) was encapsulated in the interior
cavity of RGD-conjugated HFn (RGD
+) and non-tar-
geted HFn (RGD
-) at loading factors of 5000Fe per cage,
giving R2 values of 93 mM
-1s
-1 (magnetite diameter: 5-
7nm). The injected dose was adjusted to 25mgFe/kg in
each animal.
3) MRI - All mice were imaged on a whole-body 3T
MRI scanner (Signa HDx, GE Healthcare) with a phased
array mouse coil (RAPID MR International), using a
gradient echo sequence (TR/TE=100ms/10ms, slice
thickness=1.0mm, FOV=3cm, matrix=256x256, FA=60,
NEX=10). Mice were then injected with either RGD
+ or
RGD
- (6 AAA and 4 control mice for each), followed by
MRI at 24 and 48 hours post injection. The nanoparticle
accumulation was assessed by measuring the reduction
in the T2*-weighted signal intensity of the AAA (or
suprarenal aorta in control mice) relative to adjacent
normal-size aorta (expressed as % SI loss).
4) Histology - The aortic wall was stained with Perl’s
iron (for nanoparticle accumulation), CD-11b (for
macrophages), and CD-31 (for endothelial cells).
Results
MRI showed greater T2
* signal loss in the AAA with
RDG
+ than with RDG
- (Fig 1(A)), confirmed by
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p=0.01). Abdominal aortic diameter on ultrasound cor-
related more strongly with % SI loss with RDG
+ than
with RDG
- (Fig 2(B)). Perl’s iron staining confirmed
greater accumulation of RDG
+ in the AAA compared to
RGD
- (474±51 vs. 277±29 stained cells/cross-sectional
area, p=0.01), with colocalization to both macrophages
(CD-11b) and endothelial cells (CD-31) within the AAA
wall (Fig 2(C)).
Conclusions
HFn iron-oxide nanoparticles with RGD targeting pro-
vide a promising MRI approach for comprehensive in
vivo detection of inflammation and angiogenesis in
high-risk AAAs.
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